Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,452,653 papers from all fields of science
Search
Sign In
Create Free Account
HKI 272
Known as:
HKI-272
, HKI272
An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile, irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
neratinib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Antineoplastic combination comprising hki-272 and vinorelbine
Чарльз Захарчук
2013
Corpus ID: 132931683
1. A method for treating a neoplasm in a subject, which comprises administering a vinorelbine ukazannyysposob or an analogue…
Expand
2011
2011
Cancer Therapy : Preclinical Antitumor Efficacy of PKI-587 , a Highly Potent Dual PI 3 K / mTOR Kinase Inhibitor
R. Mallon
,
Larry R. Feldberg
,
+8 authors
I. Hollander
2011
Corpus ID: 36528041
Purpose: The aim of this study was to show preclinical efficacy and clinical development potential of PKI-587, a dual…
Expand
2011
2011
A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments w
A. Seyhan
,
U. Varadarajan
,
+7 authors
T. Ryan
2011
Corpus ID: 145817427
ErbB2 is frequently activated in tumors, and influences a wide array of cellular functions, including proliferation, apoptosis…
Expand
2010
2010
Abstract P3-14-05: Safety and Efficacy of Neratinib (HKI-272) Plus Vinorelbine in the Treatment of Patients with ErbB2+ Metastatic Breast Cancer Pretreated with Anti-HER2 Therapy
E. Starosławska
,
L. Dirix
,
+11 authors
A. Awada
2010
Corpus ID: 72623331
Background: Neratinib (HKI-272) is an irreversible pan-ErbB tyrosine kinase inhibitor that blocks downstream signaling of the…
Expand
2010
2010
Abstract 647: Xenograft Models of Breast Cancer: the Link between Characteristics of Biomarker Expression and the Anti-tumor Effect of the Representative Therapies
Juan Zhang
,
Z. Guan
,
Xiaomin Song
,
Taiping Chen
,
J. Wery
,
Yiyou Chen
2010
Corpus ID: 76477127
Gene expression analysis has led to the identification of 5 subtypes of breast cancer (basal-like, HER2-like, luminal A and B…
Expand
2009
2009
Antineoplastic combinations containing HKI-272 and vinorelbine
查尔斯.扎查丘克
2009
Corpus ID: 109354439
A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and…
Expand
2009
2009
Wherein containing Hki-272 and vinorelbine neoplastic combination
찰스 자카르축
2009
Corpus ID: 104314678
신생물 치료에서의 HKI-272…
Expand
2009
2009
APhase I Study with Neratinib ( HKI-272 ) , an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor , in Patients with Solid Tumors
Kwok-kin Wong
,
P. Fracasso
,
+14 authors
H. Burris
2009
Corpus ID: 6354922
Purpose: The dose-limiting toxicities, maximum tolerated dose, pharmacokinetic profile, and preliminary antitumor activity of…
Expand
2009
2009
Combinaisons antinéoplasiques contenant du HKI-272 et de la vinorelbine
Charles Zacharchuk
2009
Corpus ID: 194570818
Review
2007
Review
2007
ProspectiveAssessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by theAddition of Everolimus
Gregory Riely
,
M. Kris
,
+8 authors
A. Miller
2007
Corpus ID: 23576634
Purpose:Ten percent of U.S. patients with non ^ small cell lung cancer experience partial radiographic responses to erlotinib or…
Expand